Community participatory groups to prevent and control Type II diabetes in rural Peshawar and Swabi
Official title: Engagement of coMmunity Through Participatory Learning and Action for cOntrol and preVEntion of Type II Diabetes and Its Risk Factors [EMPOWER-D]: Cluster Randomized Controlled Trial
Run by Khyber Medical University Peshawar · NCT06561126 · Data updated 2026-11-12
This project will try a community group-based Participatory Learning and Action program to help prevent and control Type II diabetes among adults living in rural Peshawar and Swabi, Pakistan.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 20 Years and up |
| Sex | All |
| Enrollment | 12744 (estimated) |
| Sponsor | Khyber Medical University Peshawar Academic / other |
| Locations | 1 site (Peshawar, KPK) |
| Status | Recruiting |
| Started | May 1, 2025 |
| Main results expected | May 30, 2026 |
| Study ends | August 31, 2026 |
| Registry record updated | September 2, 2025 |
| Trial ID | NCT06561126 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 20 years and older who live in the rural areas of Peshawar or Swabi, are willing to consent, and can attend scheduled community group meetings are ideal candidates.
✕Probably not a fit
People who cannot attend or participate in regular group activities, have severe health conditions that prevent active involvement, or require intensive medical management rather than community support may not benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The trial adapts a Participatory Learning and Action (PLA) approach—using community groups that follow cycles of problem identification, collaborative planning, action, and participatory evaluation—to address Type II diabetes and intermediate hyperglycemia. It will be delivered in rural clusters in Peshawar and Swabi and tailored to local needs, using methods such as photo-voice, group discussion, and role-play. A cluster randomized controlled design will compare PLA intervention clusters to control clusters to measure impact on diabetes prevention and control outcomes. Adults aged 20 and over across the glycemic spectrum (normoglycemia, pre-diabetes, and diabetes) will be invited to participate and attend regular local group meetings.
Why it matters
Potential benefit: If successful, the program could reduce new diabetes cases and improve self-care and prevention behaviors by empowering local communities to adopt healthier practices.
How similar studies have gone: PLA approaches have demonstrated effectiveness for maternal and neonatal health in South Asia and informed diabetes-focused community programs such as D-Magic Bangladesh, providing precedent though community PLA for diabetes control remains less widely validated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Individuals aged 20 years and above. * Participants residing in the rural areas of Peshawar and Swabi, Pakistan. * Individuals willing to participate in the study and provide consent. * Both individuals with normoglycemia, intermediate hyperglycemia, and diabetes are encouraged to participate. * Participants who can attend the scheduled meetings and interventions as per the study protocol. Exclusion Criteria: * Individuals below the age of 20 years. * Individuals unwilling to provide consent for participation. * Participants with severe health conditions that may hinder their active involvement in the study. * Individuals with a history of non-compliance with medical interventions or research protocols
Where it's running
-
Khyber Medical University Peshawar
Peshawar, Kpk, Pakistan Recruiting
Study contacts
- Principal investigator: Prof. Dr Zia Ul Haq, MBBS,MPH,PhD — Khyber Medical Univeristy Peshawar
- Study coordinator: Prof. Dr Zia Ul Haq, MBBS,MPH,PhD
- Email: drzia@kmu.edu.pk
- Phone: +92 333 9258763
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Effect of kidney function on GL0034 exposure in adults with type 2 diabetes
We will give a single dose of GL0034 to adults with type 2 diabetes who have different levels of kidney function to see if kidney problems change how the body handles the drug.
-
Community participatory learning to prevent and control type 2 diabetes in rural Kabul
This project will try a community-led participatory learning and action program to prevent and control type 2 diabetes among adults living in rural Kabul.
-
Weekly GL0034 injections for overweight or obese adults with type 2 diabetes
This study will try weekly GL0034 injections to see if they lower HbA1c and are tolerated in overweight or obese adults with type 2 diabetes.
-
Community engagement to prevent Type II diabetes in urban Pakistan
This study is trying a community-based program in urban Karachi to see if it can help prevent and manage Type II diabetes for people aged 20 and older.
-
Empagliflozin with or without metformin for safety and tolerability in adults with Type 2 diabetes
This project will try empagliflozin, with or without metformin, in adults with Type 2 diabetes to see if it is safe and well tolerated in routine clinical care at participating centers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.